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Abstract 
In this study, we have examined the role of
post-translational modification of the myeloid
master regulator C/EBPa by small ubiquitin-
related modifier (SUMO). We have used tran-
sient  transfection  analysis,  oligonucleotide
pulldown  assays  and  chromatin  immuno-
precititation in all-trans retinoic acid (ATRA)-
inducible promyelocytic cell lines MPRO and
NB4.  We  demonstrate  that  sumoylated  wild-
type p42-C/EBPa is associated with negative
regulation of the myeloid specific lactoferrin
(LF)  gene  in  early  myeloid  cells  and  that  a
reduction  in  p42-C/EBPa sumoylation  coin-
cides with expression of the LF gene in matur-
ing myeloid cells. In the acute promyelocytic
leukemia cell line NB4 however, sumoylated
p42 remains persistently bound to the LF pro-
moter  following  ATRA-induction.  This  corre-
lates  with  lack  of  lactoferrin  expression  in
these cells. Changes in sumoylation status of
C/EBPa thus appear to contribute to a switch
that regulates transcriptional activity of this
master  regulator  during  normal  neutrophil
development.  We  also  demonstrate  that
sumoylation of the AML associated dominant
negative  p30-C/EBPa isoform  does  not  alter
transactivation  activity  of  the  LF  promoter.
This may be because the p30 C/EBPa isoform
binds to the LF promoter much less efficiently
than its full length counterpart. Our data sug-
gest  that  the  activity  of  p42-C/EBPa in  the
developing  neutrophil  is  more  sensitive  to
changes in sumoylation than the p30 isoform.
This difference may contribute to the leuke-
mogenic potential of p30-C/EBPa.
Introduction
C/EBPa is the founding member of a family
of basic region/leucine zipper (bzip) transcrip-
tion factors that is a master regulator of gran-
ulopoiesis.1 It  is  expressed  at  high  levels
throughout myeloid differentiation and binds
to the promoters of multiple myeloid- specific
genes at different stages of myeloid matura-
tion. Several groups have reported mutations
in the C/EBPa gene in a subset of patients
with AML with normal karyotype.2 These muta-
tions  can  be  classified  into  two  main  cate-
gories. The first includes in-frame mutations
clustered in the C-terminus of the C/EBPapro-
tein. This domain harbors the conserved basic-
region  leucine-zipper  responsible  for  DNA
binding, as well as the dimerization domain.
Often  additional  mutations  in  the  second
C/EBPa allele  accompany  these  mutations
resulting  in  functional  loss  of  C/EBPa.  The
second category of mutations involves the N-
terminus of C/EBPa. These frame-shift muta-
tions are responsible for premature termina-
tion  of  the  full  length  p42  C/EBPa isoform
while keeping the truncated p30C/EBPa pro-
tein  intact.2 The  remaining  p42C/EBPa is
thought to be rendered inactive by the domi-
nant-negative activity of the p30 isoform by an
unknown  mechanism.3,4 More  recently,  mice
engineered  to  express  only  the  p30  isoform
from  the  C/EBPa locus  developed  AML  with
complete  penetrance.5 This  highlights  the
functional differences between the full length
p42 isoform, with its tumor suppressive activi-
ty,  compared  to  the  truncated  p30  C/EBPa,
which has leukemogenic potential.5
C/EBPa potently activates myeloid differen-
tiation. However, chromatin immunoprecipita-
tion studies from our laboratory have previous-
ly demonstrated that C/EBPa associates with
the promoters of late myeloid genes such as
lactoferrin  (LF)  in  immature  neutrophils
where  LF  is  not  expressed.  Upon  induction
towards neutrophil maturation C/EBPe binds
to the LF promoter which correlates with LF
expression. This suggests that C/EBPa associ-
ates with a DNA binding complex that nega-
tively  regulates  LF  gene  expression.6 In  an
attempt to understand the mechanism under-
lying  this  observation,  we  hypothesized  that
the negative regulatory effect of C/EBPa may
be due in part, to post-translational modifica-
tion(s) of the C/EBPa protein. In this regard,
C/EBPa was recently shown to be post-transla-
tionally  modified  by  small  ubiquitin-related
modifier (SUMO) at a lysine residue (K159)
within a region of the C/EBPa protein that can
negatively  affect  transcriptional  activity.7,8
Sumoylation at K159 in the C/EBPa protein is
thought to prevent association of the SWI/SNF
chromatin remodeling complex with C/EBPa,
thereby  hampering  transactivation.
Sumoylation of p42-C/EBPahas been shown to
be increased in p30-C/EBPa expressing AMLs
via  a  mechanism  that  upregulates  Ubc9,  a
Sumo  E2  conjugating  enzyme  essential  for
Sumoylation,  in  a  p30-C/EBPa dependent
manner.8 The authors however do not explain
if upregulation of Ubc9 has a functional effect
on sumoylation of p30-C/EBPaitself. We there-
fore chose to examine the impact of sumoyla-
tion on the activity of both isoforms of C/EBPa
during myeloid differentiation and to ascertain
their potential impact on leukemogenesis.
Materials and Methods
Tissue culture, transient transfec-
tion and luciferase assays
HEK293T (293T) cells were a gift from Dr.
Ghosh  (Yale  University  School  of  Medicine,
New Haven, CT), MPRO cells obtained from Dr.
Schickwann  Tsai  (University  of  Utah,  Salt
Lake City, UT) and NB4 cells were grown as
previously described.6,9,10 All cells were main-
tained at 37ºC in a humidified 5% CO2 incuba-
tor. HEK293T cells were transfected with the
previously described LF89 lactoferrin reporter
plasmid11 using  FuGene  (Roche  Applied
Sciences) according to the manufacturer’s pro-
tocol 0.5 mg pCMVbgal (Clontech, Palo Alto,
CA,  USA),  was  cotransfected  as  an  internal
control  plasmid  to  monitor  transfection  effi-
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ciency as previously described.12 Transfected
cells were incubated at 37ºC in 5% CO2 for 16-
20 hours. Luciferase activity was determined
using a kit from Promega Biotech (Madison,
WI) per manufacturer’s instructions. Co-trans-
fection  experiments  included  1  mm  of
pCDNA3.1 C/EBPa p42, pCDNA3.1C/EBPap30,
(a gift from Dr. Peter Johnson, NCI-Frederick,
MD), or pCMV Flag SUMO1 (a gift form Dr. N.
Nucifora, University of Illinois, Chicago, USA).
Mutant K159A p42 construct was a gift from Dr.
K  Miyake  (Nayoga  University,  Japan)  while
K159A  p30  was  constructed  by  mutating  a
lysine (K) residue to an alanine residue (A) in
the p30 cDNA using the QuikChange II method
per  manufacturers  instructions  (Stratagene,
La Jolla, CA, USA). Luciferase expression lev-
els were normalized to levels of b-galactosi-
dase expression.12
RNA isolation and northern blot
analysis
Total  RNA  was  extracted  from  uninduced
and ATRA-induced MPRO and NB4 cells as pre-
viously  described,  and  10  mm  analyzed  by
northern blot analysis. Blots were probed with
cDNA probes for mouse or human lactoferrin
as described elsewhere.11
Oligonucleotide pulldown assay
This assay was conducted as previously doc-
umented.13 Briefly,  uninduced  and  48hour
ATRA-induced MPRO or NB4 cells were lysed
in NP-40 lysis buffer (50 mM Tris-Hcl (pH 8.0),
0.5% NP-40, 150 mM NaCl, 0.1 mM EDTA, 1mM
DTT, 10% glycerol and the complete protease
inhibitor  cocktail  (Roche).  200  mm  of  cell
lysates or nuclear extracts (NE-PER kit) were
incubated  with  20  mm  of  double–stranded
biotinylated oligonucleotide probes correspon-
ding  to  the  C/EBP  site  in  the  LF  promoter.
LF/C/EBP  WT:5’GTCTATTGGGCAACAGG  3’  or
mut  LF/C/EBP  5’GTCTAGGTTTACGCAGG3’
DNA-protein  complexes  were  then  collected
and resolved in a 4-12% gradient NuPage gel
(Invitrogen). Western blotting was performed
as  described  below.  Antibodies  used  were:
C/EBPe (Santa  Cruz  Biotech,  sc-158,
1:3000), Sumo-1 (Santa Cruz Biotech, 1:1000)
and  C/EBPa (Santa  Cruz  Biotech,  sc-61,
1:3000) antibodies in TBS-T incubated at 4°C
overnight.
Chromatin immunoprecipitation
analysis 
ChIP analysis was performed essentially as
previously  described6 using  the  following
oligomers:  Human  LF  C/EBP:  FP:
TGGCGGGGAGTGGGAGGGAA;  RP:
AAGCTTGTCGACCGACTTGGCAAACGAAG  and
HNP: FP: 5’GTCAACTGTGTTAGGAGCCAT3’; RP:
5’CGTGCACAAGTGGACTTC3’  PCR  products
were  subcloned  into  the  pCRII  vector
(Invitrogen)  and  sequenced  by  standard
dideoxy  sequencing  technology  to  confirm
their identity.
Results
Oligonucleotide pull-down analysis
of C/EBPa and C/EBPe during
myeloid differentiation of ATRA-
induced MPRO cells 
In order to analyze the in vivo protein-DNA
interactions at the C/EBP binding site in the
lactoferrin promoter during myeloid differenti-
ation,  we  performed  an  oligonucleotide  pull
down  assay  (OPD),  using  MPRO  cells  as  a
model  for  neutrophil  differentiation.  MPRO
cells are a factor-dependent promyelocytic cell
line  harboring  a  dominant  negative  RARa
gene. These cells undergo neutrophil matura-
tion upon addition of pharmacological levels of
ATRA resulting in high levels of LF expression
as evidenced in the northern blot (Figure1A).
Biotinylated  oligomers  representing  the
LF/C/EBP binding site in the LF promoter were
used.  Nuclear  extracts  were  first  prepared
from HEK293T cells transfected with a C/EBPa
expression  plasmid.  The  DNA-protein  com-
plexes formed were recovered using strepta-
vidin–agarose  beads  and  bound  proteins
resolved by SDS-PAGE and western blot analy-
sis. As shown in Figure 1B (lanes 1 and 2),
C/EBPa bound to the LF/C/EBP probe very effi-
ciently  and  was  enriched  over  input  levels
(lane 3, In). To assay for binding of endoge-
nous C/EBPa to the probe, the experiments
were then repeated using nuclear extracts pre-
pared  from  uninduced  and  ATRA-induced
MPRO cells, a model for normal in vitro neu-
trophil  maturation.  Extracts  were  incubated
with either a wild type (WT) or a mutant (mut)
biotinylated  LF/C/EBP  probe.  As  shown  in
Figure 1C, C/EBPa binds to the WT LF/C/EBP
probe in uninduced MPPO cells. This binding
was  significantly  reduced  in  ATRA-induced
MPRO cell extracts. As expected, significantly
less C/EBPa binding to the mutant LF/C/EBP
probe was observed. In contrast, an increase in
C/EBPe binding to the LF/C/EBP WT probe was
observed  upon  48  h  ATRA-induction  (Figure
1C, WT oligos, lower panel), concomitant with
LF expression (Figure 1A, 24 and 48hours in
ATRA).
This  experiment  suggests  that  C/EBPa is
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Figure 1. Binding of C/EBPa to the Lactoferrin (LF) promoter and expression of the LF
gene  during  neutrophil  maturation  in  ATRA-induced  MPRO  cells.  A.  Northern  blot
analysis of uninduced and ATRA-induced MPRO cells demonstrating an increase in LF
mRNA expression upon ATRA-treatment of cells for 24 and 48 hours. Ethidium bromide-
stained 28S rRNA in the lower panel serves as a loading control. B. Oligonucleotide pull
down  assay  using  LF  C/EBP  oligomers  and  extracts  prepared  from  HEK293T  cells.
Nuclear extracts prepared from HEK293T cells overexpressing a C/EBPa expression plas-
mid were incubated with biotinylated wildtype LF/C/EBP oligomers. The DNA-protein
complexes  were  recovered  using  streptavidin–agarose  beads  and  the  bound  proteins
resolved  by  SDS-PAGE  and  western  blot  analysis.  The  blot  was  probed  with  a
C/EBPaantibody (lanes 1 and 2). 10% of the input sample is represented in lane 3 (In).
C. Oligonucleotide pulldown assay using LF/ C/EBP oligomers and nuclear extracts from
Uninduced and induced MPRO cells. Nuclear extracts prepared from uninduced (0) and
ATRA-induced (48h) MPRO cells (a murine myeloid cell line for normal neutrophil mat-
uration) were incubated with  wild type (WT) or mutant (mut) biotinylated C/EBP site
(LF/C/EBP) oligomers from the LF promoter. The DNA-protein complexes were recov-
ered using streptavidin–agarose beads and the bound proteins resolved by SDS-PAGE and
western blot analysis. The blot was probed sequentially with C/EBPa and C/EBPe anti-
bodies. 
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bound to the LF promoter when the LF gene is
not expressed, and that induction of neutrophil
maturation  is  associated  with  reciprocal
changes in the binding of C/EBPa and C/EBPe
to the LF/C/EBP binding site, coincident with
LF  gene  expression.  We  have  previously
demonstrated this pattern of C/EBP binding to
the  LF  promoter  in  uninduced  and  induced
MPRO cells by ChIP analysis.6
Sumoylation of C/EBPa limits its
ability to transactivate the LF pro-
moter
C/EBPa is  an  established  transcriptional
activator. Our observations in Figure1 howev-
er,  suggest  that  it  negatively  regulates  the
expression LF during myeloid maturation. We
postulated  that  this  negative  regulation  by
C/EBPa with respect to LF expression could
reflect posttranslational modifications of the
C/EBPa protein and/ or changes in associa-
tions of C/EBPa with other interacting pro-
teins. As previously noted, human C/EBPa is
modified  by  SUMO-1  at  lysine  residue  159
within  a  conserved  negative  subdomain.14
Sato  et  al  have  recently  demonstrated  that
sumoylation of C/EBPa dramatically decreas-
es its ability to transactivate the liver-specific
albumin  gene.  A  second  study  also  demon-
strated a two-fold reduction in the activity of
a generic C/EBP reporter gene in the pres-
ence  of  Sumo-1.8 In  order  to  test  whether
sumoylation  of  C/EBPa alters  activation  of
the  LF  promoter,  we  co-transfected  HEK293
cells with a LF promoter-reporter gene plas-
mid  (LF89)  and  expression  plasmids  for
C/EBPa and Sumo-1. As shown in Figure 2A,
p42 C/EBPa transactivated the LF89 plasmid 7
fold.  However,  co-transfection  with  Sumo-1
markedly  reduced  reporter  gene  activity
(P<0.001). This reduction in transactivation
was not observed with a C/EBPa mutant plas-
mid incapable of being sumoylated (K159A)
(Figure 2A). In fact, this mutant increased LF
promoter activity two fold compared with the
p42  C/EBPa expression  plasmid,  possibly
reflecting loss of repression due to endoge-
nous SUMO activity, even in the absence of
the  transfected  exogenous  SUMO-1  expres-
sion  plasmid.  These  observations  suggest
that  sumoylation  of  p42  C/EBPa blocks  its
ability to transactivate the myeloid-specific LF
gene. 
Sumoylation of p30 C/EBPa does
not suppresses transactivation of
the LF promoter 
As a result of the differential utilization of
alternate  translational  start  codons,  the
C/EBPa gene yields two proteins, p42kD (full
length) and p30kD (truncated) that differ from
one  another  at  the  N-terminus  wherein  lie
potent transactivation domains. The p30 iso-
form is a less efficient transactivator than its
full  length  counterpart  and  is  considered  a
dominant negative form of C/EBPa.3 P30 has
been shown to be overexpressed in most cases
of acute myeloid leukemia (AML).2
To determine whether sumoylation has an
impact on the ability of p30 C/EBPa to transac-
tivate the lactoferrin promoter LF89, we per-
formed  transient  cotransfection  analysis  in
HEK293 cells. The p30 isoform transactivated
LF89 about 2.5- fold less efficiently than the
p42 isoform (compare Figures 2A and 2B). 
P30 C/EBPatransactivated the LF89 promot-
er reporter 3-fold above LF89 alone. However,
unlike the p42 C/EBPa plasmid, cotransfection
of p30 C/EBPa with a Sumo-1 expression plas-
mid did not significantly change LF89 activity,
nor did the sumoylation- blocking mutant p30
C/EBPa K159A (Figure 2B). This suggests that
p30 C/EBPa is much less sensitive to sumoyla-
tion than p42 C/EBPa. 
To confirm binding of the C/EBPa isoforms
to the previously defined LF C/EBP cis element,
we performed an OPD assay with the LF/C/EBP
probe and nuclear extracts prepared from both
C/EBPa p42-  and  p30-  overexpressing
HEK293T cells. Despite abundant expression
of  both  C/EBP  isoforms  in  the  respective
HEK293T cells (Figure 2C, lower panel), the
p30 isoform demonstrated negligible binding
to the LF/C/EBP probe (Figure 2C, lanes 1 and
2) as compared to the p42 isoform (Figure 2C,
lanes 3 and 4). This reduced DNA binding of
p30 has been demonstrated with other C/EBPa
specific downstream targets such as the CSF3
receptor promoter.2
Taken  together,  these  data  suggest  that
sumoylation controls the transactivition activi-
ty of the p42C/EBPa isoform but not that of the
dominant negative p30C/EBPa isoform.
Binding of sumoylated C/EBPa to
the lactoferrin promoter decreases
upon neutrophil differentiation in
ATRA-induced MPRO cells
Our finding that sumoylation of p42C/EBPa
reduces its ability to transactivate LF89 sug-
gested a possible role for the sumoylated form
of the protein in negative regulation of the LF
gene early in neutrophil development. To test
this  hypothesis,  it  was  necessary  to  demon-
strate  an  inverse  relationship  between  the
presence of sumoylated C/EBPa and the activ-
ity of the LF promoter in a physiologic context.
An OPD assay was performed on uninduced
and  induced  MPRO  cells,  with  western  blot
analysis  for  sumoylated  C/EBPa.  The  data
demonstrate that SUMO-C/EBPa is bound to
the LF/C/EBP probe in uninduced MPRO cells
(Figure 3, lane 3), and that the binding is sig-
nificantly decreased by the induction of neu-
trophil maturation (Figure 3, lane 4). Of note,
while  the  total  amount  of  SUMO-C/EBPa
remains  about  the  same  during  neutrophil
Article
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Figure 2. Transient transfection analysis of
Lactoferrin promoter (LF89) harboring a
C/EBP site in HEK293T cells with expres-
sion plasmids for the two C/EBPa isoforms
and  SUMO-1.  A.  Transient  transfection
analysis using a lactoferrin promoter plas-
mid  (LF89)  harboring  a  C/EBP  site.
HEK293T  cells  were  transiently  cotrans-
fected with LF89 and expression plasmids
for p42 C/EBPa (wild-type) or p42 K159A
(mutant)  with  and  without  SUMO-1.
Normalized luciferase (to that of b-galac-
tosidase, see Materials and Methods) values
have been represented as a fold change over
the enzyme activity of LF89 promoter plas-
mid  alone  (equal  to  1) The  figure  repre-
sents  normalized  mean+/-  s.e.  obtained
from 3independent experiments, each per-
formed in triplicate. B. Transient transfec-
tion analysis of LF89 with expression plas-
mids  for  p30C/EBPa (wild-type  or  p30
K159A mutant) with and without SUMO-
1. Analysis was done as indicated above. C.
Oligonucleotide pull down assay of LF89
oligomers  with  extracts  prepared  from
HEK293T  cells  overexpressing
p30C/EBPA  (lanes  1  and  2)  and
p42C/EBPa (lanes 3 and 4). Extracts were
incubated  with  wild  type  biotinylated
C/EBP  site  (LF/C/EBP)  oligomers  from
the LF promoter. The DNA-protein com-
plexes  were  recovered  using
streptavidin–agarose beads and the bound
proteins resolved by SDS-PAGE and west-
ern  blot  analysis  and  probed  with  a
C/EBPa specific  antibody.  Lower  panels
represents 5% of each of the input samples.
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development  in  the  MPRO  cells,  (Figure  3,
lanes 1 and 2), the amount of SUMO-C/EBPa
bound to the LF/C/EBP probe decreases with
maturation, confirming a reciprocal relation-
ship to LF expression during neutrophil devel-
opment. 
Sumoylated C/EBPa remains
bound to the LF/C/EBP site in the
acute promyelocytic cell line NB4 
NB4 is an acute promyelocytic leukemia cell
line  that  contains  the  t(15;17)  PML-RARa
translocation and undergoes neutrophil matu-
ration with addition of ATRA. We have previ-
ously demonstrated that following ATRA-induc-
tion, NB4 cells uniformly fail to express not
only LF, but all the secondary granule protein
genes.9 We further demonstrated that this fail-
ure of expression occurs despite appropriate
binding of C/EBP factors known to upregulate
LF  expression.  We  therefore  investigated
whether sumoylation of the abundantly avail-
able C/EBPa in NB4 cells contributed to the
failure of LF gene expression. In order to test
this hypothesis, we first performed ChIP analy-
sis using nuclear extracts prepared from unin-
duced and 48 hour ATRA-induced NB4 cells. As
shown in Figure 4A (upper panel), ChIP analy-
sis using a C/EBPa antibody indicated binding
of C/EBPa to the control HNP (human neu-
trophil peptide also known as a-defensin) pro-
moter in uninduced but not ATRA-induced NB4
cells. We have previously shown that the HNP
gene, encoding a late primary granule protein,
is  in  fact  expressed  in  ATRA-induced  NB4
cells.6 Binding of C/EBPa to the LF promoter,
on the other hand, persisted in both uninduced
and ATRA-induced NB4 cells corresponding to
the absence of LF expression in ATRA-induced
NB4 cells. Thus, loss of C/EBPa- binding to
myeloid  promoters  (HNP)  in  the  maturing
neutrophil is concomitant with expression of
these genes, while persistent binding parallels
nonexpression, as is the case for LF.
In  order  to  determine  whether  C/EBPa
bound  to  the  LF  promoter  in  NB4  cells  is
sumoylated, we next performed an OPD assay
using  the  LF/C/EBP  oligonucleotide  and
extracts prepared from uninduced and ATRA-
induced NB4 cells. As shown in Figure 4B (top
panel), C/EBPa binds to the LF/C/EBP site in
both uninduced and ATRA-induced NB4 cells.
In addition, the bound C/EBPa appears to be
sumoylated  in  both  uninduced  and  ATRA-
induced cells (Figure 4B, bottom panel). This
contrasts  with  the  loss  of  C/EBPa binding
upon induction observed in the ATRA-respon-
sive  LF-  expressing  MPRO  cell  line  (Figure
1B). Thus, persistent association of sumoylat-
ed C/EBPa with the LF promoter in NB4 cells
may contribute to the lack of expression of this
gene in leukemic cells.
Discussion
In this study we have demonstrated that the
sumoylation  status  of  the  C/EBPa protein
changes  during  normal  myeloid  maturation,
and that this is accompanied by changes in LF
gene expression. We postulate that changes in
the sumoylation status of C/EBPa contribute
to a switch that regulates its transcriptional
activity  during  normal  neutrophil  develop-
ment.
Sumoylation or Sumo modification is a post
translational  modification  wherein  SUMO
(small ubiquitin – like modifier) is covalently
and reversibly conjugated to its target proteins
by  a  series  of  sequential  and  evolutionarily
conserved enzymatic reactions. This results in
alteration of target protein function and cellu-
lar fate. 1,15 The list of sumoylated proteins is
rapidly  increasing  and  includes  several  that
play pivotal roles in processes as diverse as
transcriptional  regulation,  nuclear  targeting,
sub-nuclear  targeting,  chromatin  structure
and genome stability. 
We demonstrate here that the C/EBPa p42
isoform  transactivates  the  myeloid-specific
lactoferrin gene promoter approximately 3 fold
more  efficiently  than  p30  C/EBPa.
Cotransfection of p42 with an expression plas-
mid  for  SUMO-1  however,  significantly
reduces  LF89  driven  luciferase  activity  com-
pared to transfection of p42 alone. In compari-
son, SUMO-1 has little or no effect on the abil-
ity of p30C/EBPato drive LF89 luciferase activ-
ity. This suggests that sumoylation alters the
transcriptional activity of p42 but not p30 dur-
ing myeloid differentiation and further indi-
cates that sumoylation of the two C/EBPa iso-
forms may have functionally disparate effects,
possibly  due  to  differential  protein-protein
binding  properties  of  each  sumoylated  iso-
form. In this context, in a recent study, Geletu
et  al.8 showed  that  overexpression  of  p30
C/EBPa in an erythroleukemia cell line result-
ed in upregulation of Ubc9, a sumo E2 conju-
gating enzyme, which is essential for sumoyla-
tion.1 The authors demonstrate that upregula-
tion  of  Ubc9  sumoylates  the  p42  isoform,
thereby rendering it inactive with respect to
transactivation of a C/EBP- responsive reporter
plasmid in transactivation assays. The authors
further  suggest  that  sumoylation  of  p42
C/EBPa in AML may be the result of increased
expression of the p30 isoform. Our data extend
this finding by showing that sumoylated p42
remains persistently bound to the LF promoter
in the acute promyelocytic leukemia cell line
NB4 following ATRA-induction. This observa-
tion  is  correlated  with  lack  of  lactoferrin
expression in these cells. Whether binding of
sumoylated  p42  C/EBPa to  the  LF  promoter
persists  due  to  aberrant  activity  of  the
desumoylating SENP enzymes or whether an
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Figure 3. Oligonucleotide pulldown analy-
sis  of  C/EBPa and  sumoylated-C/EBPa
during  ATRA-induction  of  MPRO  cells.
Nuclear extracts prepared from uninduced
(0) and ATRA-induced (48h) MPRO cells
were incubated with  biotinylated C/EBP
site  (LF/C/EBP)  oligomers  from  the  LF
promoter and OPD conducted as above.
The  blot  was  probed  sequentially  with
anti-C/EBPa (lanes  3  and  4,  top  panel)
and anti-SUMO-1 (lanes 3 and 4, bottom
panel) antibodies. Input samples are repre-
sented  in  lanes  1  and  2  of  the  top
(C/EBPa) and bottom (SUMO-1) panels.
Figure 4. Binding of Sumoylated-C/EBPA
to  the  LF  C/EBPa oligomers  in  ATRA-
induced  NB4  leukemic  cells:  A.
Chromatin immunoprecipitation was per-
formed  from  uninduced  (0)  and  ATRA-
induced (48h) NB4 cells using antibodies
specific  for  C/EBPa.  The  precipitated
chromatin  was  analyzed  using  primers
specific for the human LF (LF) promoter
(bottom  panel)  and  the  HNP  promoter
(top panel). This experiment was repeated
three times. B. Oligonucleotide pulldown
assay of C/EBPa and sumoylated-C/EBPa
during  ATRA-induction  of  NB4  cells.
Nuclear extracts prepared from uninduced
(0) and 48h ATRA-induced NB4 cells were
incubated  with    biotinylated  C/EBP  site
(LF/C/EBP) oligomers from the LF pro-
moter and oligonucleotide pulldown assay
conducted as above. The blot was probed
sequentially with anti-C/EBPa (top panel)
and  anti-SUMO-1  (bottom  panel)  anti-
bodies.  +  represents  a  positive  control
(uninduced MPRO extracts).
C/EBPa:
C/EBPa:
C/EBPa:
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increase of p30 C/EBPa expression in these
leukemic cells causes increased rates of p42
sumoylation  remains  to  be  clarified.
Approximately  10-15%  of  AML  patients  have
mutations in C/EBPa2,16,17 that often result in
an increase in expression of p30 C/EBPa. In
fact,  a  recent  study  has  shown  that  mice
homozygously  expressing  p30  from  the
C/EBPa locus develop AML with complete pen-
etrance.5 Changes in the ratio of p42:p30 have
been found to contribute to tipping the scales
from normal myelopoiesis to pre-leukemic or
even  leukemic  myelopoiesis.2 While  the  p30
isoform is thought to exert a dominant nega-
tive effect on its full length counterpart (p42),
the mechanisms underlying this effect remain
unclear. Our data demonstrate that unlike p42,
the p30 C/EBPaisoform remains unresponsive
to sumoylation and binds poorly to the LF pro-
moter in a C/EBP binding site pulldown assay.
The  limited  ability  of  p30  to  bind  to  other
myeloid specific promoters such as the CSF3
receptor  promoter,  has  also  been  previously
reported.2 This evidence strongly suggests that
differences  in  activity  between  the  two
C/EBPa isoforms play a role in the shift from
normal myeloid development to leukemogene-
sis. 
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